CClinicalTrials.gg
Not yet recruitingNCT07364682Updated Jul 7, 2026

Measuring Heart Health in Both Term, Preterm and Unwell Newborn Babies With an Advanced Ultrasound Method: Speckle Tracking Echocardiography

An observational study in Premature Baby, Pulmonary Hypertension of Newborn and Hypoxic Ischaemic Encephalopathy (HIE), sponsored by Birmingham Women's NHS Foundation Trust. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 0 Minutes to 8 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Birmingham Women's NHS Foundation Trust · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
190
Ages
0 Minutes to 8 Weeks
Sex
All
01

Study summary

This study aims to improve how neonatologists check the heart function of newborn babies, especially those who are sick. While standard heart ultrasound scans are useful, a more advanced and sensitive technique called 2D speckle tracking echocardiography (STE) can detect subtle problems with how the heart muscle squeezes and relaxes. This may allow doctors to spot potential issues earlier.

Our research will take place at Birmingham Women's Hospital. The investigators will perform these advanced, non-invasive heart scans on several groups of babies:

  1. Healthy term and premature babies, to establish a "normal" range of heart function.
  2. Babies who are unwell with specific conditions, including those with brain injury due to lack of oxygen at birth (HIE), chronic lung disease of prematurity (BPD), a hole in the diaphragm (CDH), or high blood pressure in their lungs (aPHN).

The heart scan is a standard, painless procedure. Using STE does not require any extra scanning time or cause any additional discomfort to the baby; the special images are taken during the routine scan. For many of the sick babies, these scans are already part of their normal clinical care.

The main goals of this observational study are to see if STE is a feasible and reliable tool in newborns, to establish normal values for healthy babies, and to track how heart function changes in sick babies during their illness and recovery.

Ultimately, the investigators hope this research will provide doctors with a better tool to assess heart health in newborns. This could lead to earlier, more accurate detection of heart problems and help guide treatment decisions to improve outcomes for these vulnerable infants.

02

Conditions studied

  • Premature Baby
  • Pulmonary Hypertension of Newborn
  • Hypoxic Ischaemic Encephalopathy (HIE)
  • Congenital Diaphragmatic Hernia
  • Chronic Lung DIsease

Keywords

  • Speckle Tracking Echocardiography
  • STE
  • Functional echocardiography
  • Neonatal Performed Echocardiography
03

Who can participate

Ages eligible
0 Minutes to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Inpatient status at Birmingham Women's Hospital Neonatal Unit - only babies admitted to the neonatal unit, transitional care ward or postnatal ward will be considered for screening.

Belong to one of the following target clinical groups:

  • Group 1: Term neonates diagnosed with Hypoxic Ischaemic Encephalopathy (HIE) and receiving therapeutic hypothermia.
  • Group 2: Preterm neonates born at or before 32 weeks' gestation, who are later diagnosed with Chronic Lung Disease (CLD) requiring supplemental oxygen at 36 weeks corrected gestational age.
  • Group 3: Term neonates diagnosed with Congenital Diaphragmatic Hernia (CDH).
  • Group 4: Term neonates diagnosed with Acute Pulmonary Hypertension of the Newborn (aPHN), excluding those with CDH.
  • Healthy controls:
  • Term neonates (>36 weeks' gestation) who are well and on postnatal wards.
  • Well preterm neonates (\<36 weeks' gestation). • Stable enough for echocardiography and research inclusion, as determined by the attending physician.

Inclusion criteria

  • Neonates who are inpatient at the Birmingham Women's Hospital
  • Confirmed diagnosis of acute pulmonary hypertension, congenital diaphragmatic hernia, hypoxic ischaemic encephalopathy, or bronchopulmonary dysplasia/chronic lung disease (defined by oxygen/respiratory support requirement at 36 weeks post menstrual/corrected gestational age).

OR

  • Health control (>36 weeks - well and on the postnatal ward)
  • Well preterm neonate (\<36 weeks) admitted to the NICU, transitional care or post-natal wards.
  • Informed consent obtained from parent(s) or legal guardian(s)

Exclusion criteria

Exclusion Criteria:

  • Presence of major congenital heart disease (other than patent foramen ovale or patent ductus arteriosus).
  • Presence of other life-limiting congenital anomalies (other than CDH) or syndromes that could independently affect cardiac function.
  • Inability to obtain adequate echocardiographic images for STE analysis after reasonable attempts.
  • If the neonatal consultant or neonatal nurse caring for the neonate feels that the neonate is too unstable for inclusion in the study or that consent should not be sought from parents.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
190 participants (estimated)
Patient registry
No

Groups and cohorts

  • Congenital Diaphragmatic Hernia

    Term neonates diagnosed with Congenital Diaphragmatic Hernia (CDH)

  • Hypoxic Ischaemic Encephalopathy

    Term neonates diagnosed with Hypoxic Ischaemic Encephalopathy (HIE) and receiving therapeutic hypothermia.

  • Acute pulmonary hypertension

    Term neonates diagnosed with Acute Pulmonary Hypertension of the Newborn (aPHN), excluding those with CDH.

  • Bronchopulmonary Dysplasia

    Preterm neonates born at or before 32 weeks' gestation, who are later diagnosed with Chronic Lung Disease (CLD) requiring supplemental oxygen at 36 weeks corrected gestational age.

  • Healthy preterms

    (\<36 weeks' gestation) admitted to the NICU and transitional care. Stratified into extreme preterm, moderately preterm and late preterm.

  • Healthy term controls

    (\>36 weeks' gestation) who are well and on postnatal wards.

05

What researchers measure

Primary outcomes

  1. To assess the feasibility of acquiring adequate quality images for comprehensive Right ventricular - Speckle Tracking Echocardiography (RV-STE), Left ventricular (LV) STE, and left atrial (LA) -STE in neonates with aPHN, CDH, HIE, and BPD.

    Feasibility rate of RV, LV, and LA STE.

    Time frame: By completion of data collection (September 2027)

  2. To describe the longitudinal changes in RV, LV, and LA STE parameters from acute illness through recovery/discharge in each disease cohort.

    The invetigators will measure this by looking at values and longitudinal trends of: RV-Global Longitudinal Strain (GLS), RV-Free Wall Longitudinal Strain (FWLS), LV-GLS, LA reservoir strain (LASr) in healthy neonates and neonates with disease conditions (HIE, BPD, CDH, aPHN).

    Time frame: By September 2027

  3. To establish normative values of simultaneously performed RV, LV and LA strain in well term and preterm neonates

    The investigators will establish normative reference RV, LV and LA strain using two-dimensional speckle-tracking echocardiography in a cohort of well term and preterm neonates. Report Strain values as means ± standard deviations and percentiles (5th-95th), stratified by gestational age, postnatal age, and birth weight categories.

    Time frame: By September 2027

Secondary outcomes

  1. To evaluate the intra-observer and inter-observer reproducibility of RV, LV, and LA STE measurements

    The investigators will use intra-class correlation coefficients (ICC), Bland-Altman limits of agreement, and coefficient of variation (CV) for key STE parameters.

    Time frame: By September 2027

  2. To compare STE-derived parameters with conventional echocardiographic measures of cardiac function.

    Correlation and agreement between speckle tracking echocardiography (STE)-derived parameters (STE derived EF, STE derived TAPSE) and conventional echocardiographic measures of cardiac function (EF by Simpson Biplane technique, M-mode TAPSE).

    Time frame: By September 2027

  3. To compare RV, LV, and LA STE parameters between the different disease cohorts and a cohort of healthy control neonate

    Comparison of right ventricular (RV), left ventricular (LV), and left atrial (LA) strain and strain rate parameters derived from speckle tracking echocardiography (STE) between neonates in different disease cohorts and a healthy control group.

    Time frame: By September 2027

06

Study locations

1 site
  • Birmingham Women's Hospital
    Birmingham, B15 2TG, United Kingdom
    • Asad Abbas Dr Asad Abbas, MD MBBS MRCPCH · Contact · asad.abbas1@nhs.net · +441214721377
    • Andrew Pearce Dr Andrew Pearce, MBBS MRCPCH · Contact · andrewjames.pearce@nhs.net
    • Asad Abbas, MD MBBS MRCPCH · Principal investigator
07

References and documents

Individual participant data

Plan to share: No — The REC required removal of the proposed wording allowing anonymised participant data to be shared with external researchers on request. As participants are not being consented for future research data sharing, the study has no plan to share IPD, and the ClinicalTrials.gov IPD field is therefore recorded as "No". This is an observational trial with no intervention and not a clinical trial of a device or drug.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07364682
Lead sponsor
Birmingham Women's NHS Foundation Trust
Responsible party
Asad Abbas (Consultant Neonatologist, Birmingham Women's NHS Foundation Trust) — Principal investigator
First posted
Jan 23, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Feb 1, 2028 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
Jul 7, 2026

Study contacts

Asad Abbas Dr Asad Abbas, MD MBBS FRCPCH
Contact
asad.abbas1@nhs.net
+441214721377
Andrew Pearce Dr Andrew Pearce, MBBS MRCPCH
Contact
andrewjames.pearce@nhs.net

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion